JAZZ Jazz Pharmaceuticals
$231.39 -1.97%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.97%
YTD
+68.50%
P/E
16.23
P/B
2.39
ROE
21.4%
Div yield
—
Beta
0.53
Market cap
$15.3B
RSI (14)
38
Next earnings
Nov 3, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$236.40
Close
$231.39
VWAP (n/a)
—
Day high
$236.40
Day low
$228.70
Volume
862K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit
Yahoo Finance · Oct 6
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
Yahoo Finance · Sep 30
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Yahoo Finance · Sep 20
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Yahoo Finance · Sep 18
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet
Yahoo Finance · Sep 18
Jazz Pharmaceuticals (JAZZ) Eyes Ziihera Trials In Breast Colorectal And Lung Cancer
Yahoo Finance · Sep 14
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 23, 2026 View → 8-K Sep 15, 2026 View → 8-K Aug 31, 2026 View → 8-K Aug 25, 2026 View → 8-K Aug 10, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell JAZZ. Try it in the Lab to size a position and see the risk.